Two optimized antimicrobial peptides with therapeutic potential for clinical antibiotic-resistant Staphylococcus...

Area of Science:

• Microbiology
• Biochemistry
• Drug Discovery

Background:

• Rising Methicillin-resistant Staphylococcus aureus (MRSA) infections necessitate novel therapeutic agents due to widespread antibiotic resistance.
• Antimicrobial peptides (AMPs) represent a promising class of next-generation antibiotics with potential against resistant bacterial strains.

Purpose of the Study:

• To design and evaluate novel antimicrobial peptides with enhanced anti-MRSA activity and reduced toxicity.
• To investigate the mechanism of action of these peptides on MRSA biofilm formation and virulence.

Main Methods:

• Peptide design through amino acid substitutions to enhance amphipathicity.
• Antimicrobial activity testing against sensitive and resistant Staphylococcus aureus strains.
• Hemolysis and cytotoxicity assays using human hemocytes and renal epithelial cells.
• Scanning Electron Microscopy (SEM) and quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) to assess biofilm and gene expression.

Main Results:

• Two designed peptides, P5 and P9, demonstrated potent activity against MRSA without significant hemolysis or cytotoxicity.
• P5 and P9 effectively inhibited MRSA biofilm formation and disrupted bacterial cell membrane integrity.
• These peptides down-regulated key virulence factor and biofilm formation genes, including spa, hld, and sdrC.

Conclusions:

• Novel peptides P5 and P9 exhibit significant anti-MRSA efficacy.
• These peptides offer a dual mechanism of action by inhibiting biofilm formation and down-regulating virulence factors.
• P5 and P9 are promising candidates for developing new treatments against challenging MRSA infections.